Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer

被引:20
|
作者
Sun, Xuezheng [1 ]
Hoadley, Katherine A. [2 ,3 ]
Kim, William Y. [2 ,3 ,4 ,5 ]
Furberg, Helena [6 ]
Olshan, Andrew F. [1 ,2 ]
Troester, Melissa A. [1 ,2 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Suite 32,CVS Plaza,137 East Franklin St,CB 8050, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA
[5] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
[6] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
Muscle-invasive bladder cancer; Molecular subtype; Age; Obesity; Smoking; LUMINAL SUBTYPES; BASAL; RISK; ASSOCIATION; PROGNOSIS; SURVIVAL; PATTERNS; STAGE; GRADE;
D O I
10.1007/s10552-017-0885-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Heterogeneity of muscle-invasive bladder cancer (MIBC) has been characterized using whole-genome mRNA expression data, showing distinct molecular and clinicopathological characteristics by subtypes. However, associations between risk factors and molecular subtypes have not been reported. Methods Four previously published schemes were used to categorize molecular subtypes in 372 MIBC patients from the Cancer Genome Atlas (TCGA). Data on gene expression (RNA-seq), demographic, and clinicopathological characteristics were retrieved through TCGA data portal. Polytomous logistic regression was used to estimate the associations of subtypes by different schemes with age at diagnosis, obesity, and smoking. Results While some quantitative variation was evident, distinct molecular subtype schemes showed considerable consistency in the association with the risk factors. Generally, compared to patients with luminal-like tumors, patients with basal-like subtypes were more likely to be older (OR75 + yrs vs. < 60 years range = 1.32-2.89), obese (ORobese vs. normal range = 1.30-3.05), and to start smoking at early age (OR < 18 years vs. 25+ years range = 1.11-4.57). Conclusions Different molecular subtypes of MIBC may have distinct risk profiles. Large population-based studies with detailed information on bladder cancer risk factors are needed to further define etiologic heterogeneity for bladder cancer.
引用
收藏
页码:539 / 544
页数:6
相关论文
共 50 条
  • [21] Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
    Miyamoto, David T.
    Mouw, Kent W.
    Feng, Felix Y.
    Shipley, William U.
    Efstathiou, Jason A.
    LANCET ONCOLOGY, 2018, 19 (12): : E683 - E695
  • [22] Bladder preservation in muscle-invasive bladder cancer
    Stackl, W
    Baierlein, M
    Albrecht, W
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (03): : 357 - 360
  • [23] Bladder conservation for muscle-invasive bladder cancer
    Hoskin, Peter
    Dubash, Suraiya
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (08) : 1015 - 1020
  • [24] Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes
    Ruan, Jia-Ling
    Hsu, Jong-Wei
    Browning, Richard J.
    Stride, Eleanor
    Yildiz, Yesna O.
    Vojnovic, Borivoj
    Kiltie, Anne E.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (03): : 239 - 247
  • [25] Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
    Seiler, Roland
    Ashab, Hussam Al Deen
    Erho, Nicholas
    van Rhijn, Bas W. G.
    Winters, Brian
    Douglas, James
    Van Kessel, Kim E.
    van de Putte, Elisabeth E. Fransen
    Sommerlad, Matthew
    Wang, Natalie Q.
    Choeurng, Voleak
    Gibb, Ewan A.
    Palmer-Aronsten, Beatrix
    Lam, Lucia L.
    Buerki, Christine
    Davicioni, Elai
    Sjodahl, Gottfrid
    Kardos, Jordan
    Hoadley, Katherine A.
    Lerner, Seth P.
    McConkey, David J.
    Choi, Woonyoung
    Kim, William Y.
    Kiss, Bernhard
    Thalmann, George N.
    Todenhofer, Tilman
    Crabb, Simon J.
    North, Scott
    Zwarthoff, Ellen C.
    Boormans, Joost L.
    Wright, Jonathan
    Dall'Era, Marc
    van der Heijden, Michiel S.
    Black, Peter C.
    EUROPEAN UROLOGY, 2017, 72 (04) : 544 - 554
  • [26] Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis
    Schallenberg, Simon
    Dragomir, Mihnea-Paul
    Anders, Philipp
    Ebner, Benedikt
    Volz, Yannic
    Eismann, Lennert
    Rodler, Severin
    Casuscelli, Jozefina
    Buchner, Alexander
    Klauschen, Frederick
    Stief, Christian
    Horst, David
    Schulz, Gerald Bastian
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 788 - 798
  • [27] Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer
    Koll, Florestan J.
    Doering, Claudia
    Herwig, Leon
    Hoeh, Benedikt
    Wenzel, Mike
    Garcia, Cristina Cano
    Banek, Severine
    Kluth, Luis
    Koellermann, Jens
    Weigert, Andreas
    Chun, Felix K-H
    Wild, Peter
    Reis, Henning
    JOURNAL OF CLINICAL PATHOLOGY, 2025, 78 (01) : 19 - 27
  • [28] Re: A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer
    不详
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1223 - 1224
  • [29] Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer
    Saito, Ryoichi
    Kobayashi, Takashi
    Ogawa, Osamu
    EUROPEAN UROLOGY, 2018, 73 (05) : 808 - 809
  • [30] Chemotherapy for Muscle-Invasive Bladder Cancer
    Patrizia Trenta
    Fabio Calabrò
    Linda Cerbone
    Cora N. Sternberg
    Current Treatment Options in Oncology, 2016, 17